Opyl (ASX:OPL) signed a service level agreement with Avion, a full-service contract research organization that delivers end-to-end clinical trial solutions, the company said in a Friday Australian bourse filing.
The partnership combines Avion's expertise in clinical trial management with Opyl's proprietary TrialKey platform, delivering data-driven insights to optimize trial design and improve outcomes, the filing said.
Under the agreement, Opyl and Avion will integrate Opyls's proprietary TrialKey platform into clinical trial planning and execution, and the company will provide Avion with reports and insights for AU$5,000 per report, according to the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。